AwesomeCapital

Meridian Bioscience sees Q1 revenue $51M-51.5M, consensus $53.5M

https://thefly.com/landingPageNews.php?id=2845031

Diplomat downgraded to Market Perform from Outperform at William Blair

https://thefly.com/landingPageNews.php?id=2844939

Sarepta’s ‘unfounded’ weakness a buying opportunity, says RBC Capital

RBC Capital analyst Brian Abrahams believes there has been some confusion coming out of an investor presentation this morning on Sarepta’s limb girdle muscular dystrophy data and on the regulatory path for microdystrophin gene therapy. After talking with the company, he believes timelines and prospects for both remain intact, views the weakness as “‘unfounded” and would use the pullback today as a buying opportunity. Abrahams maintains an Outperform rating on Sarepta shares.
https://thefly.com/landingPageNews.php?id=2844941

Syndax initiated at B. Riley FBR

Syndax resumed with a Buy at B. Riley FBR. B. Riley FBR analyst Polishetty resumed coverage on Syndax with a Buy and $40 price target.
https://thefly.com/landingPageNews.php?id=2844949

Apellis initiated at B. Riley FBR

Apellis initiated at B. Riley FBR Apellis resumed with a Buy at B. Riley FBR. B. Riley FBR analyst Polishetty resumed coverage on Apellis with a Buy and $40 price target.
https://thefly.com/landingPageNews.php?id=2844951

Immunomedics initiated at B. Riley FBR

Immunomedics resumed with a Buy at B. Riley FBR. B. Riley FBR analyst Harshita Polishetty resumed coverage on Immunomedics with a Buy and $55 price target.
https://thefly.com/landingPageNews.php?id=2844953

Amgen makes all Repatha device options available in U.S. at 60% reduced price

Amgen announced that all Repatha device options, including the Pre-Filled Syringe and Pushtronex (on-body infusor with prefilled cartridge), are now available at a 60% reduced list price of $5,850 per year. The most commonly used delivery system, the Repatha SureClick autoinjector, was made available at the lower list price of $5,850 on Oct. 24, 2018. The lower priced Repatha options are identical to the Repatha options currently available, but have been introduced to reduce out-of-pocket costs for patients, especially Medicare patients.
https://thefly.com/landingPageNews.php?id=2844971